[{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tasquinimod","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tasquinimod","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tasquinimod","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Laquinimod","moa":"Aryl hydrocarbon receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Active Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tasquinimod","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Oncode Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Tasquinimod","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Active Biotech \/ Oncode Institute","highestDevelopmentStatusID":"4","companyTruncated":"Active Biotech \/ Oncode Institute"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Laquinimod","moa":"Aryl hydrocarbon receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Active Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Active Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Famar","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GREECE","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Laquinimod","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Active Biotech \/ Active Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Active Biotech \/ Active Biotech"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Active Biotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Tasquinimod","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Active Biotech \/ Active Biotech","highestDevelopmentStatusID":"6","companyTruncated":"Active Biotech \/ Active Biotech"},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Naptumomab Estafenatox","moa":"||5T4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Active Biotech \/ NeoTX Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ NeoTX Therapeutics"},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Naptumomab Estafenatox","moa":"||5T4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Active Biotech \/ NeoTX Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ NeoTX Therapeutics"},{"orgOrder":0,"company":"Active Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Naptumomab Estafenatox","moa":"||5T4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Active Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Active Biotech","sponsor":"NeoTX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Antibody-drug Conjugate","year":"2020","type":"Licensing Agreement","leadProduct":"Naptumomab Estafenatox","moa":"||5T4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Active Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Active Biotech \/ NeoTX Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Active Biotech \/ NeoTX Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Active Biotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Under the terms of the agreement, Wistar grants Active Biotech a global exclusive license to develop and commercialize tasquinimod in combination therapy, as a treatment for multiple myeloma.

Product Name : ABR-215050

Product Type : Small molecule

Upfront Cash : Undisclosed

May 22, 2024

Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide

Therapeutic Area : Oncology

Highest Development Status : Phase I

Recipient : Wistar Institute of Anatomy and Biology

Deal Size : Undisclosed

Deal Type : Acquisition

blank

02

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Laquinimod is a first-in-class immunomodulator that induces immune tolerance and reduces the pro-inflammatory and angiogenic response by targeting of the myeloid cell compartment.

Product Name : TV-5600

Product Type : Small molecule

Upfront Cash : Not Applicable

April 26, 2022

Lead Product(s) : Laquinimod

Therapeutic Area : Ophthalmology

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Under the terms of the agreement, Oncode Institute, a foundation under the laws of the Netherlands, acting on behalf of Erasmus Universiteit Medisch Centrum, grants a global exclusive license to develop and commercialize tasquinimod worldwide in MF to Ac...

Product Name : Undisclosed

Product Type : Small molecule

Upfront Cash : Undisclosed

February 09, 2022

Lead Product(s) : Tasquinimod

Therapeutic Area : Oncology

Highest Development Status : Preclinical

Sponsor : Oncode Institute

Deal Size : Undisclosed

Deal Type : Licensing Agreement

blank

04

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Preclinical data on drug tasquinimod, a small molecule immunomodulator Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects by Inhibiting c-Myc Expression in Vitro and In Vivo.

Product Name : Undisclosed

Product Type : Small molecule

Upfront Cash : Not Applicable

December 15, 2021

Lead Product(s) : Tasquinimod

Therapeutic Area : Oncology

Highest Development Status : Phase I/ Phase II

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

05

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : A preclinical program shows that the laquinimod eye-drop is safe and well tolerated, and the safety of this new formulation will now be tested in a phase I clinical study in healthy subjects.

Product Name : ABR-215062

Product Type : Small molecule

Upfront Cash : Not Applicable

December 10, 2021

Lead Product(s) : Laquinimod

Therapeutic Area : Ophthalmology

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

06

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Naptumomab estafenatox (NAP) is a cell therapy candidate, currently in Phase I. It is in clinical development for advanced solid tumors utilizing its proprietary Tumor Targeted Superantigen platform.

Product Name : ABR-217620

Product Type : Antibody-drug Conjugate

Upfront Cash : Inapplicable

November 30, 2021

Lead Product(s) : Naptumomab Estafenatox,Durvalumab

Therapeutic Area : Oncology

Highest Development Status : Phase I

Sponsor : NeoTX Therapeutics

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

07

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Tasquinimod is an oral immunomodulatory and anti-angiogenic investigational treatment, that affects the tumor’s ability to grow and metastasize. Tasquinimod is developed as a new immunomodulatory treatment for multiple myeloma.

Product Name : Undisclosed

Product Type : Small molecule

Upfront Cash : Not Applicable

October 03, 2021

Lead Product(s) : Tasquinimod,Ixazomib Citrate,Lenalidomide

Therapeutic Area : Oncology

Highest Development Status : Phase I

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

08

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : The study was amended to also include assessment of pre-treatment with obinutuzumab to assess its effect on anti-drug antibodies (ADAs) to naptumomab.

Product Name : ABR-217620

Product Type : Antibody-drug Conjugate

Upfront Cash : Inapplicable

July 05, 2021

Lead Product(s) : Naptumomab Estafenatox,Durvalumab

Therapeutic Area : Oncology

Highest Development Status : Phase I/ Phase II

Sponsor : NeoTX Therapeutics

Deal Size : Inapplicable

Deal Type : Inapplicable

blank

09

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : Through the agreement, Active Biotech will get the material for the clinical development of the eye-drop formulation of ABR-215062 (laquinimod), which is used for the treatment of non-infectious non-anterior uveitis.

Product Name : ABR-215062

Product Type : Small molecule

Upfront Cash : Undisclosed

February 04, 2021

Lead Product(s) : Laquinimod

Therapeutic Area : Ophthalmology

Highest Development Status : Phase I

Recipient : Famar

Deal Size : Undisclosed

Deal Type : Agreement

blank

10

BePharma
Not Confirmed
BePharma
Not Confirmed

Details : In 2016, Active Biotech and NeoTX entered into a partnership for the development and commercialization of naptumomab in cancer indications.

Product Name : ABR-217620

Product Type : Antibody-drug Conjugate

Upfront Cash : Undisclosed

December 11, 2020

Lead Product(s) : Naptumomab Estafenatox,Durvalumab

Therapeutic Area : Oncology

Highest Development Status : Phase I

Sponsor : NeoTX Therapeutics

Deal Size : $71.0 million

Deal Type : Licensing Agreement

blank